REG - Adv Medical Solutns. - Results of Annual General Meeting

Advanced Medical SolutionsAnnouncement

Yesterday 13:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250630:nRSd0203Pa&default-theme=true

RNS Number : 0203P  Advanced Medical Solutions Grp PLC  30 June 2025

30 June 2025

 

Advanced Medical Solutions Group plc

("AMS" or the "Group")

 

Results of Annual General Meeting

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the
world-leading specialist in tissue-healing technologies, announces that at the
Company's Annual General Meeting held today at 11 am at the Offices of
Investec Bank plc, 30 Gresham Street, London, EC2V 7QP, all resolutions were
duly passed. Further details of each of the resolutions are set out in the
Notice of Meeting, which was sent to shareholders on 3 June 2025.

 

The poll results were as follows.

 

 Resolution  Title                 For          For %   Against    Against %  Total Votes  % Issued Capital
 1           FINANCIAL STATEMENTS  135,778,231  100%    3,706      0.00%      135,781,937  61.93%
 2           REMUNERATION REPORT   133,782,863  98.47%  2,082,282  1.53%      135,865,145  61.97%
 3           AUDITOR REMUNERATION  134,051,574  98.61%  1,891,541  1.39%      135,943,115  62.01%
 4           RE-ELECT G COOK       126,950,171  93.38%  8,992,839  6.62%      135,943,010  62.01%
 5           RE-ELECT D LE FORT    128,280,815  94.36%  7,662,195  5.64%      135,943,010  62.01%
 6           ELECT S SEARLE        135,889,875  99.96%  53,135     0.04%      135,943,010  62.01%
 7           RE-ELECT C MEREDITH   134,405,209  98.87%  1,537,801  1.13%      135,943,010  62.01%
 8           RE-ELECT E JOHNSON    133,759,281  98.39%  2,183,729  1.61%      135,943,010  62.01%
 9           FINAL DIVIDEND        135,944,832  100%    1,706      0.00%      135,946,538  62.01%
 10          ALLOT SHARES*         135,266,755  99.50%  679,783    0.50%      135,946,538  62.01%
 11          PRE-EMPTION RIGHTS*   134,287,332  98.78%  1,658,642  1.22%      135,945,974  62.01%
 12          PURCHASE SHARES*      134,630,774  99.98%  27,900     0.02%      134,658,674  61.42%

*  Special Resolution

 Notes:

 1.  Votes "For" and "Against" are expressed as a percentage of votes
 received.

 2.  A "Vote withheld" is not a vote in law and is not counted in the
 calculation of the votes "For" or "Against" a resolution.

 3.  Total number of shares in issue at close of business on 26 June =
 219,243,007 shares. 62.01% of the voting capital was instructed.

 

 

 

 

 

 

 

 

 

- End -

 

For further information, please visit www.admedsol.com
(http://www.admedsol.com) or contact:

 

 Advanced Medical Solutions Group plc             Tel: +44 (0) 1606 545508
 Chris Meredith, Chief Executive Officer

 Eddie Johnson, Chief Financial Officer

 Michael King, Investor Relations

 ICR Healthcare                                   Tel: +44 (0) 20 3709 5700
 Mary-Jane Elliott / Lucy Featherstone            AMS@icrhealthcare.com

 Investec Bank PLC (NOMAD & Broker)               Tel: +44 (0) 20 7597 5970
 Gary Clarence / David Anderson

 Berenberg (Joint Broker)                         Tel: +44 (0)20 3207 7800
 Toby Flaux / Detlir Elezi / Yasmina Benchekroun

 

About Advanced Medical Solutions Group plc - see www.admedsol.com
(http://www.admedsol.com)

AMS is a world-leading independent developer and manufacturer of innovative
tissue-healing technology, focused on quality outcomes for patients and value
for payers. AMS has a wide range of surgical products including tissue
adhesives, sutures, haemostats, internal fixation devices and internal
sealants, which it markets under its brands LiquiBand®, RESORBA®,
LiquiBandFix8®, LIQUIFIX™, Peters Surgical, Ifabond, Vitalitec and
Seal-G®. AMS also supplies wound care dressings such as silver alginates,
alginates and foams through its ActivHeal® brand as well as under white
label. Since 2019, the Group has made seven acquisitions: Sealantis, an
Israeli developer of innovative internal sealants, Biomatlante, a French
developer and manufacturer of surgical biomaterials, Raleigh, a leading UK
coater and converter of woundcare and bio-diagnostics materials, AFS Medical,
an Austrian specialist surgical business, Connexicon, an Irish tissue
adhesives specialist, Syntacoll, a German specialist in collagen-based
absorbable surgical implants and Peters Surgical, a global provider of
specialty surgical sutures, mechanical haemostasis and internal cyanoacrylate
devices.

 

AMS's products, manufactured in the UK, Germany, France, the Netherlands,
Thailand, India, the Czech Republic and Israel, are sold globally via a
network of multinational or regional partners and distributors, as well as via
AMS's own direct sales forces in the UK, Germany, Austria, France, Poland,
Benelux, India, the Czech Republic and Russia. The Group has R&D
innovation hubs in the UK, Ireland, Germany, France and Israel. Established in
1991, the Group has more than 1,600 employees. For more information, please
see www.admedsol.com (http://www.admedsol.com) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGSDIFESEISEEM